Personal information

No personal information available

Activities

Collapse all

Works (4)

In silico-guided discovery and in vitro validation of novel sugar-tethered lysinated carbon nanotubes for targeted drug delivery of doxorubicin

Journal of Molecular Modeling
2024-08 | Journal article
DOI: 10.1007/s00894-024-06061-5
Contributors: Chanchal Kiran Thakur; Fábio G. Martins; Chandrabose Karthikeyan; Subhasmita Bhal; Chanakya Nath Kundu; N. S. Hari Narayana Moorthy; Sérgio F. Sousa
Source: check_circle
Crossref

Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation

Medical Oncology
2024-01-06 | Journal article
DOI: 10.1007/s12032-023-02279-0
Contributors: Saptarshi Sinha; Subarno Paul; Sushree Subhadra Acharya; Chinmay Das; Somya Ranjan Dash; Subhasmita Bhal; Rajalaxmi Pradhan; Biswajit Das; Chanakya Nath Kundu
Source: check_circle
Crossref

Targeting crosstalk of signaling pathways in cancer stem cells: a promising approach for development of novel anti-cancer therapeutics

Medical Oncology
2023-01-20 | Journal article
DOI: 10.1007/s12032-022-01905-7
Contributors: Subhasmita Bhal; Chanakya Nath Kundu
Source: check_circle
Crossref

Organocatalyzed umpolung addition for synthesis of heterocyclic-fused arylidene-imidazolones as anticancer agents.

Bioorganic & medicinal chemistry
2022-05-20 | Journal article
DOI: 10.1016/j.bmc.2022.116835
PMID: 35617791
Source: Self-asserted source
Subhasmita Bhal
How many people are using ORCID?